Areteia Therapeutics Secures $75M Boost in Series A Funding
February 20, 2024, 10:57 am
Areteia Therapeutics, a biotech company based in Chapel Hill, NC, has clinched an additional $75 million in Series A financing. This injection of funds brings their total funding to a staggering $425 million.
The round of funding was backed by heavyweights like Viking Global Investors and Marshall Wace, who joined the original group of investors led by Bain Capital Life Sciences. Other key players in this funding round include Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.
Areteia Therapeutics, under the leadership of CEO Jorge Bartolome, is on a mission to develop groundbreaking therapies in the field of Inflammation and Immunology. Their flagship drug candidate, dexpramipexole, aims to revolutionize the treatment of eosinophilic asthma by targeting eosinophilic inflammation.
The company is currently in the advanced stages of developing dexpramipexole, with three Phase III clinical trials underway in collaboration with Validae Health, a unit of Population Health Partners.
This latest funding boost will fuel the expansion of Areteia's Phase III development program for dexpramipexole, bringing hope to respiratory patients battling eosinophilic asthma.
In a competitive landscape where innovation is key, Areteia Therapeutics stands out as a beacon of hope for patients seeking better control over their respiratory conditions. With this fresh infusion of funds, the company is poised to make significant strides in the fight against eosinophilic asthma.
The round of funding was backed by heavyweights like Viking Global Investors and Marshall Wace, who joined the original group of investors led by Bain Capital Life Sciences. Other key players in this funding round include Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.
Areteia Therapeutics, under the leadership of CEO Jorge Bartolome, is on a mission to develop groundbreaking therapies in the field of Inflammation and Immunology. Their flagship drug candidate, dexpramipexole, aims to revolutionize the treatment of eosinophilic asthma by targeting eosinophilic inflammation.
The company is currently in the advanced stages of developing dexpramipexole, with three Phase III clinical trials underway in collaboration with Validae Health, a unit of Population Health Partners.
This latest funding boost will fuel the expansion of Areteia's Phase III development program for dexpramipexole, bringing hope to respiratory patients battling eosinophilic asthma.
In a competitive landscape where innovation is key, Areteia Therapeutics stands out as a beacon of hope for patients seeking better control over their respiratory conditions. With this fresh infusion of funds, the company is poised to make significant strides in the fight against eosinophilic asthma.